Special Issue on Immunotherapy and Radiotherapy – from Radiobiology to Clinical Practice

Submission Deadline: Jun. 30, 2020

Please click the link to know more about Manuscript Preparation: http://www.crjournal.org/submission

This special issue currently is open for paper submission and guest editor application.

Please download to know all details of the Special Issue

Special Issue Flyer (PDF)
  • Lead Guest Editor
    • Camil Ciprian Mirestean
      Medical Oncology and Radiotherapy Department, University of Craiova, Craiova, Romania
  • Guest Editor
    Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to complete the Guest Editor application.
    • Calin Buzea
      Medical Physics Department, Regional Institute of Oncology, Iasi, Romania
  • Introduction

    In the last decades the technological advances in the field of radiotherapy and the implementation of the concepts of multimodal treatments in the therapeutic approach of cancer have changed the toxicity profile of the treatments. The implementation of image guided radiotherapy (IGRT) and the use of the intensity modulated irradiation technique led to a reduction of the doses received by the radiosensitive organs with expected results a reduction of the toxicity. The use of multimodale treatments including chemotherapy, molecular target therapy and immunotherapy often bring the benefit of the tumoricidal synergistic effect but also increase the risk of toxicity. Progress in identifying molecular, genetic or imaging markers of response to therapy has led to a refinement of radiobiological concepts regarding tumor radiosensitivity. Improving survival in metastatic disease in many locations has made it necessary to reassess the risk of late toxicity of old therapeutic protocols. In this context, the identification of dose-volume toxicity correlations and the choice between the clinical and therapeutic biological particularities of optimal radiotherapy schemes regarding the benefit-toxicity ratio becomes desirable. From the radiobiological point of view: reactivation of anti-tumor immune response is considered the 6th R of radiobiology with significant therapeutic implications. Creating multivariable radiobiological models that can be used in clinical routine is also a priority of translational research in radiobiology and radiation oncology.
    Aims and Scope:
    1. Radiobiology
    2. Radiotherapy
    3. Radiosensitivity
    4. Synergy
    5. Toxicity
    6. Dosimetry

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.crjournal.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.

  • Published Papers

    The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.